Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hepatology

Life After Treatment: Monitoring and Long-Term Health

At a Glance

After treatment for Budd-Chiari syndrome, long-term care focuses on protecting your liver through regular monitoring of shunts (TIPS) with ultrasounds, taking lifelong blood thinners to prevent new clots, and getting specialized screenings for liver cancer.

Managing Budd-Chiari Syndrome (BCS) is a marathon, not a sprint. Once your initial treatment is successful, the focus shifts to “protecting the progress.” This means a lifelong commitment to monitoring your liver’s “plumbing” and staying ahead of potential complications through regular screening.

Keeping the “Plumbing” Open

Whether you have a stent or a TIPS, these artificial pathways can sometimes narrow over time—a process called restenosis. Detecting this early is critical for preventing a recurrence of symptoms.

Doppler Ultrasound

This is the most common tool used to monitor your veins or shunts. It uses sound waves to measure the speed and direction of blood flow [1]. Your doctor will likely schedule these scans every 3 to 6 months in the first year, and potentially every 6 to 12 months thereafter, to ensure everything is flowing smoothly [2][3].

  • Warning Signs of Shunt Failure: If your shunt blocks abruptly, you need to recognize the warning signs. Contact your doctor immediately if you experience rapid abdominal swelling, sudden weight gain, or a return of severe abdominal pain [4].

Transient Elastography (FibroScan)

This is a newer, non-invasive test that measures liver stiffness.

  • The “Decompression” Signal: After a successful TIPS or stent procedure, your liver stiffness should gradually decrease as the “traffic jam” of blood is cleared [5][6].
  • Early Warning: If your liver stiffness starts to rise again on a FibroScan, it may be an early signal that your shunt is narrowing, even before you feel any symptoms [5][4].

Cancer Surveillance: Staying One Step Ahead

Patients with chronic BCS have a significantly higher risk of developing hepatocellular carcinoma (HCC), a type of liver cancer [7][8]. Surprisingly, this risk exists even for patients who do not have full-blown cirrhosis [8].

Why Screening is Challenging

In BCS, the liver is often filled with regenerative nodules—harmless lumps created as the liver tries to heal itself. On a standard CT scan, these can look identical to cancer [9][10].

  • Enhanced MRI: To tell the difference, specialists often use gadoxetic acid-enhanced MRI. This specialized contrast agent is absorbed differently by healthy liver tissue versus cancer cells, making it much more accurate for BCS patients [11][12].
  • AFP Testing: You will also likely have regular blood tests for alpha-fetoprotein (AFP), a protein that can act as a “marker” for liver cancer [13][7].

Daily Life and Long-Term Management

Living with BCS requires adjusting to a “new normal” that includes managing both your liver health and your blood’s tendency to clot.

Managing Ascites at Home

If you are prone to fluid buildup, your daily routine will likely include sodium restriction (eating a low-salt diet) and daily weight monitoring. Weighing yourself every morning is a simple but powerful way to detect fluid accumulation early—a sudden jump of a few pounds over a couple of days is a signal to call your doctor [14].

Lifelong Anticoagulation

Almost all BCS patients must remain on blood thinners for life [15]. Whether you are taking warfarin or a newer DOAC (like Eliquis), consistency is vital to prevent new clots from forming in your liver or elsewhere [16][17].

  • Bleeding Risks: Because your blood is thinner, you are at a higher risk of bleeding. Seek emergency medical care if you experience signs of internal bleeding, such as black or tarry stools, vomiting blood, or severe, sudden headaches [16].
  • Safety Tips: Consider wearing a medical alert bracelet. Always inform any dentist or surgeon that you are on lifelong anticoagulation before any procedure.

Managing the Root Cause

If your BCS was caused by an underlying blood disorder like a Myeloproliferative Neoplasm (MPN), your care will involve a “tag-team” approach between your hepatologist and a hematologist [18][2]. While the liver specialist watches your shunts, the hematologist will monitor your blood counts and the underlying genetic drivers of your condition.

By staying diligent with your monitoring schedule, you can catch any issues early and ensure your liver continues to function well for years to come.

Return to the Budd-Chiari Syndrome Resource Guide.

Common questions in this guide

How often do I need an ultrasound to check my TIPS or stent?
Doppler ultrasounds are typically scheduled every 3 to 6 months in the first year after your procedure, and every 6 to 12 months after that to ensure blood is flowing properly through your shunt.
What are the warning signs that my liver stent or shunt is failing?
Abrupt failure or narrowing of a shunt can cause rapid abdominal swelling, sudden weight gain, or a return of severe abdominal pain. Contact your doctor immediately if you experience these warning signs.
Why do I need special MRI scans for liver cancer screening?
Budd-Chiari syndrome often causes harmless regenerative nodules in the liver that look exactly like cancer on standard CT scans. A specialized gadoxetic acid-enhanced MRI can accurately tell the difference between healthy tissue and cancer cells.
Will I need to take blood thinners forever after Budd-Chiari syndrome?
Yes, almost all patients treated for Budd-Chiari syndrome must remain on blood thinners for the rest of their lives to prevent new blood clots from forming in the liver or other parts of the body.
How can I manage fluid buildup (ascites) at home?
Managing fluid buildup usually involves following a low-salt diet and weighing yourself every morning. A sudden jump of a few pounds over a couple of days is an early sign of fluid accumulation and should be reported to your doctor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should I have a Doppler ultrasound to check the patency of my TIPS or stent?
  2. 2.What was my baseline liver stiffness (FibroScan) score after my procedure, and what increase in score should we worry about?
  3. 3.Given the 'noisy' appearance of my liver due to regenerative nodules, would you recommend a gadoxetic acid-enhanced MRI for my cancer screenings?
  4. 4.How frequently will we test my alpha-fetoprotein (AFP) levels?
  5. 5.If my underlying cause is an MPN, how will you and my hematologist coordinate my long-term care?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Ultrasound Characteristics of Budd-Chiari Syndrome: A Multicenter Analysis.

    Daza J, Wiest I, Cui XW, et al.

    Digestive diseases (Basel, Switzerland) 2026; (44(2)):192-205 doi:10.1159/000549007.

    PMID: 41729746
  2. 2

    Pediatric Hepatic Venous Outflow Tract Obstruction: Experience from a Transplant Center.

    Malik I, Bhatia V, Kumar K, et al.

    Indian pediatrics 2019; (56(11)):965-967.

    PMID: 31729328
  3. 3

    Primary Budd-Chiari syndrome due to lupus anticoagulant positive antiphospholipid syndrome.

    J U S, Premkumar S, Sivaprakasam E

    BMJ case reports 2025; (18(10)) doi:10.1136/bcr-2025-267045.

    PMID: 41151826
  4. 4

    Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome.

    Dajti E, Ravaioli F, Colecchia A, et al.

    Canadian journal of gastroenterology & hepatology 2019; (2019()):1673197 doi:10.1155/2019/1673197.

    PMID: 30719429
  5. 5

    Clinical Utility of Transient Elastography in the Management of Patients with Budd-Chiari Syndrome Undergoing Endovascular Intervention.

    Anand A, Biswas S, Vaishnav M, et al.

    Journal of vascular and interventional radiology : JVIR 2022; (33(3)):268-277.e3 doi:10.1016/j.jvir.2021.11.003.

    PMID: 34798289
  6. 6

    Utility of Hepatic 2D Shear-Wave Elastography in Monitoring Response to Image-Guided Intervention in Children With Chronic Budd-Chiari Syndrome: A Prospective Study.

    Dohare N, Madhusudhan KS, Malik R, et al.

    AJR. American journal of roentgenology 2022; (218(3)):534-543 doi:10.2214/AJR.21.26547.

    PMID: 34585610
  7. 7

    Characteristics of hepatocellular carcinoma in Egyptian patients with primary Budd-Chiari syndrome.

    Sakr M, Abdelhakam SM, Dabbous H, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):415-422 doi:10.1111/liv.13219.

    PMID: 27507647
  8. 8

    Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis.

    Li KS, Guo S, Chen YX, Zhang ZL

    Frontiers in oncology 2022; (12()):1075685 doi:10.3389/fonc.2022.1075685.

    PMID: 36568193
  9. 9

    Large Regenerative Nodules and Focal Nodular Hyperplasia-Like Lesions: Definition, Pathogenesis, and Imaging Findings.

    Nolan PE, Catania R, Vendrami CL, et al.

    Radiologic clinics of North America 2022; (60(5)):795-808 doi:10.1016/j.rcl.2022.05.004.

    PMID: 35989045
  10. 10

    Budd-Chiari Syndrome and hepatic regenerative nodules: Magnetic resonance findings with emphasis of hepatobiliary phase.

    Mamone G, Carollo V, Di Piazza A, et al.

    European journal of radiology 2019; (117()):15-25 doi:10.1016/j.ejrad.2019.05.015.

    PMID: 31307641
  11. 11

    Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.

    Zech CJ, Ba-Ssalamah A, Berg T, et al.

    European radiology 2020; (30(1)):370-382 doi:10.1007/s00330-019-06369-4.

    PMID: 31385048
  12. 12

    Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.

    Joo I, Kim SY, Kang TW, et al.

    Radiology 2020; (296(2)):335-345 doi:10.1148/radiol.2020192275.

    PMID: 32484414
  13. 13

    Hepatocellular carcinoma as a complication of chronic Budd-Chiari syndrome (BCS) in a child.

    Sharma D, Khera S, Saravagi G, Dhaman PK

    BMJ case reports 2024; (17(8)) doi:10.1136/bcr-2024-261764.

    PMID: 39216892
  14. 14

    Milestones in the discovery of Budd-Chiari syndrome.

    Zanetto A, Pellone M, Senzolo M

    Liver international : official journal of the International Association for the Study of the Liver 2019; (39(7)):1180-1185 doi:10.1111/liv.14088.

    PMID: 30843330
  15. 15

    A case of Budd-Chiari syndrome with acute venous thrombosis and liver failure: highlighting the importance of early intervention and anticoagulation therapy.

    Otoyama Y, Kimura M, Nishikawa K, et al.

    Clinical journal of gastroenterology 2025; (18(4)):689-694 doi:10.1007/s12328-025-02135-w.

    PMID: 40272714
  16. 16

    Direct Oral Anticoagulants in Budd-Chiari Syndrome.

    Thapa SB, Souza GR, Paravathaneni M, et al.

    European journal of haematology 2025; (114(3)):566-572 doi:10.1111/ejh.14363.

    PMID: 39688028
  17. 17

    Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention.

    Sharma S, Kumar R, Rout G, et al.

    Journal of gastroenterology and hepatology 2020; (35(4)):654-662 doi:10.1111/jgh.14843.

    PMID: 31476024
  18. 18

    Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.

    De Stefano V, Qi X, Betti S, Rossi E

    Thrombosis and haemostasis 2016; (115(2)):240-9 doi:10.1160/TH15-04-0326.

    PMID: 26333846

This page provides educational information on the long-term management of Budd-Chiari syndrome. Always consult your hepatologist or hematologist for personalized monitoring, cancer screening, and care recommendations.

Get notified when new evidence is published on Budd-Chiari syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.